Clinical Study
Hospital-Acquired Infection Underlies Poor Functional Outcome in Patients with Prolonged Length of Stay
Table 1
Admission demographic information.
| | LOS not prolonged | LOS prolonged | value |
| Age, median y; IQR | 62; 54, 76 | 67; 57, 78 | 0.0952 | Race, (%) | | | 0.3994 | Black | 113 (67.3%) | 76 (71.7%) | | White | 51 (30.4%) | 27 (25.5%) | | Other | 2 (2.3%) | 3 (2.8%) | | Gender, female (%) | 97 (57.7%) | 69 (65.1%) | 0.2249 | In-hospital stroke, (%) | 1 (0.6%) | 0 (0.0%) | 0.6131 | Delay from LSN to ED, median; IQR | 237; 61–775 | 330; 77–728 | 0.4107 | Past medical history, (%) | | | | Stroke | 72 (42.9%) | 47 (44.3%) | 0.8095 | Coronary artery disease | 31 (18.6%) | 28 (26.4%) | 0.1245 | Diabetes mellitus | 55 (32.9%) | 39 (37.5%) | 0.4425 | Hypertension | 131 (78.4%) | 87 (83.6%) | 0.2929 | Atrial fibrillation | 17 (10.2%) | 8 (7.7%) | 0.4820 | Dyslipidemia | 76 (45.8%) | 42 (40.4%) | 0.3841 | Admission NIHSS, median; IQR | 5; 2, 13.5 | 9; 4, 17 | 0.0010 | Admission glucose, median mg/dL; IQR | 114; 95, 148 | 121; 100, 148 | 0.2248 | Admission hematocrit, median%; IQR | 39.3; 35.9, 42.5 | 39.4; 35.3, 43.3 | 0.9477 | TOAST, (%) | | | 0.1078 | Cardioembolic | 45 (26.8%) | 30 (28.3%) | | Large vessel | 35 (20.8%) | 35 (33.0%) | | Small vessel | 37 (22.0%) | 21 (19.8%) | | Unknown etiology | 35 (20.8%) | 17 (16.0%) | | More than one etiology | 7 (4.2%) | 1 (0.9%) | | Stroke Location, (%) | | | | MCA territory | 109 (64.9%) | 64 (60.4%) | 0.4517 | ACA territory | 31 (18.5%) | 11 (10.4%) | 0.0708 | PCA territory | 30 (17.9%) | 13 (12.3%) | 0.2151 | Other territory | 27 (16.1%) | 12 (11.3%) | 0.2730 | Treatment with IV tPA, (%) | 64 (38.1%) | 35 (33.0%) | 0.3943 |
|
|
LOS: length of stay; IQR: interquartile range; LSN: last seen normal; ED: emergency department; NIHSS: National Institutes of Health Stroke Scale score; TOAST: Trial of org 10172 in acute stroke treatment; MCA: middle cerebral artery; ACA: anterior cerebral artery; PCA: posterior cerebral artery; IV tPA: intravenous tissue plasminogen activator.
|